Schedule-Dependent Antitumor Activity and Toxicity of Combinations of 5-Fluorouracil and Cisplatin/Carboplatin against L1210 Leukemia-Bearing Mice(Biopharmacy)
スポンサーリンク
概要
- 論文の詳細を見る
The combination of cisplatin (CDDP) and 5-fluorouracil (5-FU) has been reported to show marked therapeutic effects on experimental tumors and human malignancies, such as head and neck cancer. In these clinical studies, CDDP was administered on day 1 and followed by a 5-d continuous infusion of 5-FU. However, it was repeatedly shown that the sequence of 5-FU followed by CDDP is more active and less toxic in tumor-bearing animals. Thus, the optimal administration schedule of CDDP and 5-FU against L1210 murine leukemia was examined and compared with that of the combination of 5-FU and carboplatin (JM-8). The combinations of 5-FU (days 1 to 5) and CDDP, given either on day 1 or on day 5, showed a similar level ofantitumor activity and toxicity. On the other hand, the combinations of 5-FU (days 1 to 5) and JM-8 given on day 5 showed significantly higher antitumor activity and rather less toxicity, as compared with the combinations on the reverse sequence. Thus, the treatment sequence of platinum compounds followed by a 5-d continuous infusion of 5-FU in many clinical studies appears to be extremely favorable to CDDP than JM-8. In addition, pathological examinations of died mice showed that accumulation of ascites and pleural effusion was inhibited most effectively by JM-8, given alone or in combination with 5-FU. These results strongly suggest that the combination of 5-FU followed by JM-8 will be expected to show more excellent antitumor activity against human malignancies, and may be especially useful in patients who are unable to tolerate CDDP-related toxicity.
- 公益社団法人日本薬学会の論文
- 2006-11-01
著者
-
Fujimoto Shuichi
Div. Of Chemotherapy Chiba Cancer Center Res. Inst.
-
Fujimoto Shuichi
Division Of Chemotherapy Chiba Cancer Center Research Institute
関連論文
- A COMPARISON OF A NEW NITROSOUREA DERIVATIVE, 1-(2-CHLOROETHYL)-3-ISOBUTYL-3-(β-MALTOSYL)-1-NITROSOUREA WITH VARIOUS ANTITUMOR AGENTS WITH RESPECT TO THERAPEUTIC RATIOS IN L1210 LEUKEMIA SYSTEMS
- Schedule-Dependent Antitumor Activity and Toxicity of Combinations of 5-Fluorouracil and Cisplatin/Carboplatin against L1210 Leukemia-Bearing Mice(Biopharmacy)
- Promising Antitumor Activity of a Novel Quinoline Derivative, TAS-103, against Fresh Clinical Specimens of Eight Types of Tumors Measured by Flow Cytometric DNA Analysis(Highlighted paper selected by Editor-in-chief,Biopharmacy)
- Schedule-dependent and -independent Antitumor Activity of Paclitaxel-based Combination Chemotherapy against M-109 Murine Lung Carcinoma in vivo
- ENHANCED ANTITUMOR ACTIVITY OF 5'-DEOXY-5-FLUOROURIDINE AGAINST LEWIS LUNG CARCINOMA IN AGED HYBRID (C57BL/6×DBA/2) F_1 MICE